Skip to main content
DONGWHA PHARM.CO.,LTD logo

DONGWHA PHARM.CO.,LTD — Investor Relations & Filings

Ticker · 000020 ISIN · KR7000020008 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 000020

About DONGWHA PHARM.CO.,LTD

https://www.dong-wha.co.kr

Dongwha Pharm is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a diverse range of healthcare products. Its portfolio includes ethical (prescription) pharmaceuticals, over-the-counter (OTC) drugs, medical devices, quasi-drugs, health functional foods, cosmetics, and beverages. The company's research and development efforts focus on various therapeutic areas, including alimentary and cardiovascular systems. Dongwha Pharm actively pursues innovation through its drug pipeline, clinical trials, and strategic investments in emerging fields like digital therapeutics.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is a comprehensive quarterly report (“분기보고서”) covering the 98th fiscal term (2026-01-01 to 2026-03-31) with detailed financial statements, segment reporting, business overview, capital changes, and subsidiary information. It is not a brief announcement or certification but the full interim financial report itself, matching the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 80% confidence The document is a Korean regulatory disclosure titled “공정거래 자율준수프로그램 운영현황(안내공시)” which outlines the Compliance Program (CP) Q1 2026 performance and Q2 2026 plan. It is not an earnings announcement, financial report, proxy statement, or executive change notice. It provides operational details of a compliance program as a statutory announcement. There is no indication it is an investor presentation or report publication notice; rather, it is the substantive disclosure itself. Since it does not fit any specialized category, it falls under the fallback Regulatory Filings category.
2026-04-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 88% confidence The document is a regulatory submission to the Financial Supervisory Service/KRX detailing the appointment of outside directors (사외이사 신규선임) for Donghwa Pharmaceutical Co., Ltd., including names, birth dates, appointment dates, and career backgrounds. This is an announcement of changes in the company’s board of directors. It matches the “Board/Management Information” category.
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is a detailed report of an Annual General Meeting (AGM) held on 2026-03-26. It lists the approval of financial statements, dividend resolution, election of directors and auditors, meeting date, record date, and voting results for each agenda item (e.g., approval rates, resolutions passed). This corresponds precisely to Declaration of Voting Results & Voting Rights Announcements. Hence, the correct classification is DVA.
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a formal 'Independent Auditor's Report' (감사보고서) for Dongwha Pharm Co., Ltd., covering the fiscal years 2024 and 2025. It includes the auditor's opinion, key audit matters, and the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. Since this is a comprehensive annual financial report containing audited financial statements, it is classified as an Annual Report (10-K). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 96% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Dongwha Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, equity, revenue, profit) for both consolidated and separate financial statements. While it contains financial data, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as an Audit Report/Information filing. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.